Strategic Focus Target rare disease programs with precision genetic medicine capabilities, especially Duchenne and myotonic dystrophy, to align Sarepta's strong portfolio with unmet patient needs and growing demand for advanced therapies.

Clinical Momentum Capitalize on recent positive preclinical and clinical data for SRP-1003 and ELEVIDYS to open co-development or expansion talks with larger biopharma and specialty investors seeking late-stage proof-of-concept signals and expanded label opportunities.

Geographic & Market Reach Leverage Sarepta’s established US headquarters and global engagement at major congresses to pursue international collaborations, manufacturing partnerships, and regional access programs in Europe and Asia for its DMD and DM1 programs.

Financial & Scale Position with potential partners who value innovative gene therapies alongside Sarepta’s sizable funding runway and revenue trajectory, highlighting opportunities for co-investment, risk-sharing, or strategic licensing to accelerate development timelines.

Technology Stack Fit Propose integrated solutions and services that resonate with Sarepta’s tech stack (AWS, SAP, Oracle Cloud, GitLab, Azure) for scalable data management, regulatory reporting, and collaboration, creating a compelling case for technology-led partnerships or vendor consolidations.